Bridgecreek Investment Management LLC Boosts Stake in IDEXX Laboratories, Inc. (IDXX)
Bridgecreek Investment Management LLC lifted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.7% in the fourth quarter, Holdings Channel reports. The institutional investor owned 66,090 shares of the company’s stock after buying an additional 6,405 shares during the quarter. IDEXX Laboratories comprises about 2.4% of Bridgecreek Investment Management LLC’s investment portfolio, making the stock its 7th biggest position. Bridgecreek Investment Management LLC’s holdings in IDEXX Laboratories were worth $10,335,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of IDXX. Koch Industries Inc. lifted its stake in shares of IDEXX Laboratories by 44,533.1% during the 2nd quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock worth $1,391,000 after buying an additional 1,396,113 shares during the last quarter. Atlantic Trust Group LLC acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter worth about $65,381,000. Old Mutual Global Investors UK Ltd. lifted its stake in shares of IDEXX Laboratories by 60.1% during the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 830,379 shares of the company’s stock worth $129,115,000 after buying an additional 311,712 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of IDEXX Laboratories by 48.7% during the 3rd quarter. American Century Companies Inc. now owns 715,175 shares of the company’s stock worth $111,203,000 after buying an additional 234,197 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of IDEXX Laboratories by 30.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 955,225 shares of the company’s stock worth $148,527,000 after buying an additional 220,818 shares during the last quarter. Institutional investors own 86.72% of the company’s stock.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at $176.83 on Thursday. IDEXX Laboratories, Inc. has a 1 year low of $140.63 and a 1 year high of $198.73. The company has a market cap of $15,420.00, a PE ratio of 60.15, a P/E/G ratio of 2.22 and a beta of 0.58. The company has a debt-to-equity ratio of -11.26, a quick ratio of 0.80 and a current ratio of 0.97.
In other IDEXX Laboratories news, VP Brian P. Mckeon sold 6,602 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $181.36, for a total value of $1,197,338.72. Following the transaction, the vice president now directly owns 47,040 shares of the company’s stock, valued at approximately $8,531,174.40. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Chairman Jonathan W. Ayers sold 36,000 shares of the firm’s stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $179.28, for a total transaction of $6,454,080.00. Following the completion of the transaction, the chairman now directly owns 1,077,112 shares in the company, valued at $193,104,639.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 100,762 shares of company stock worth $16,732,324. 2.77% of the stock is owned by insiders.
A number of analysts have recently issued reports on IDXX shares. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 target price for the company in a research note on Tuesday, October 24th. Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, October 24th. BidaskClub lowered shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday, December 16th. Aegis reaffirmed a “sell” rating on shares of IDEXX Laboratories in a research report on Friday, December 8th. Finally, Piper Jaffray Companies started coverage on shares of IDEXX Laboratories in a research report on Tuesday, January 16th. They set an “overweight” rating and a $200.00 price target on the stock. One analyst has rated the stock with a sell rating, five have assigned a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $194.00.
ILLEGAL ACTIVITY NOTICE: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.thecerbatgem.com/2018/02/08/bridgecreek-investment-management-llc-boosts-stake-in-idexx-laboratories-inc-idxx.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.